Aging and inflammation go hand in hand, so developing a drug to block the inflammation-causing multiprotein complex NLRP3 was ...
Artificial-intelligence-powered drug developer Insilico Medicine is set for a $10 million upfront payment from a fresh-faced Chinese biotech for half of the rights to a brain-penetrant NLRP3 inhibi | ...
Brenig has launched an early Phase 1 trial to evaluate BT-409, its experimental small molecule therapy, in healthy volunteers ...
News-Medical.Net on MSN
AI-designed NLRP3 inhibitor receives FDA clearance for Parkinson disease trials
Insilico Medicine (3696.HK), a clinical-stage drug discovery and development company driven by generative artificial ...
BGE-102 has the potential for therapeutic retinal exposure with oral delivery, reducing treatment burden in ocular indications currently treated with intravitreal therapies Growing preclinical and ...
Insilico Medicine (3696.HK), a clinical-stage drug discovery and development company driven by generative artificial ...
California-based biotech BioAge Labs has today announced that it is expanding development of BGE-102, its oral NLRP3 ...
"NLRP3 Protein Inhibitors Clinical Trials"NLRP3 protein inhibitors companies are Halia Therapeutics, Ventus Therapeutics, EpicentRx, Zydus Lifesciences Limited, Monte Rosa Therapeutics, Inflammasome ...
A team led by UT Southwestern Medical Center researchers has uncovered a molecular pathway that links obesity to widespread ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results